Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Gyre Therapeutics (GYRE) over the last 9 years, with Sep 2025 value amounting to -$1,000.

  • Gyre Therapeutics' Other Operating Expenses fell 100.01% to -$1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year increase of 11.80%. This contributed to the annual value of $61.5 million for FY2024, which is 2367.10% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Other Operating Expenses stood at -$1,000, which was down 100.01% from $16.3 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Operating Expenses ranged from a high of $19.1 million in Q2 2023 and a low of -$57.2 million during Q2 2022.
  • In the last 3 years, Gyre Therapeutics' Other Operating Expenses had a median value of $13.5 million in 2024 and averaged $10.1 million.
  • Per our database at Business Quant, Gyre Therapeutics' Other Operating Expenses plummeted by 5,125.90% in 2022 and then soared by 2,886.50% in 2024.
  • Gyre Therapeutics' Other Operating Expenses (Quarterly) stood at $2.5 million in 2021, then crashed by 102.40% to -$59,000 in 2022, then plummeted by 3,603.39% to -$2.2 million in 2023, then soared by 925.22% to $18.0 million in 2024, then crashed by 100.01% to -$1,000 in 2025.
  • Its Other Operating Expenses stands at -$1,000 for Q3 2025, versus $16.3 million for Q2 2025 and $11.7 million for Q1 2025.